152 related articles for article (PubMed ID: 23846576)
1. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.
Kerr SE; Schnabel CA; Sullivan PS; Zhang Y; Huang VJ; Erlander MG; Brachtel EF; Dry SM
Mod Pathol; 2014 Jan; 27(1):44-54. PubMed ID: 23846576
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
3. Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary.
Chauhan A; Farooqui Z; Silva SR; Murray A; Hodges KB; Yu Q; Myint ZW; Raajesekar AK; Weiss H; Arnold S; Evers BM; Anthony L
Asian Pac J Cancer Prev; 2019 Jan; 20(1):113-116. PubMed ID: 30678389
[TBL] [Abstract][Full Text] [Related]
4. An integrated tool for determining the primary origin site of metastatic tumours.
Santos MTD; Souza BF; Cárcano FM; Vidal RO; Scapulatempo-Neto C; Viana CR; Carvalho AL
J Clin Pathol; 2018 Jul; 71(7):584-593. PubMed ID: 29248889
[TBL] [Abstract][Full Text] [Related]
5. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin.
Rosenwald S; Gilad S; Benjamin S; Lebanony D; Dromi N; Faerman A; Benjamin H; Tamir R; Ezagouri M; Goren E; Barshack I; Nass D; Tobar A; Feinmesser M; Rosenfeld N; Leizerman I; Ashkenazi K; Spector Y; Chajut A; Aharonov R
Mod Pathol; 2010 Jun; 23(6):814-23. PubMed ID: 20348879
[TBL] [Abstract][Full Text] [Related]
6. Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer.
Kulkarni A; Pillai R; Ezekiel AM; Henner WD; Handorf CR
Diagn Pathol; 2012 Aug; 7():110. PubMed ID: 22909314
[TBL] [Abstract][Full Text] [Related]
7. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.
Maxwell JE; Sherman SK; Stashek KM; O'Dorisio TM; Bellizzi AM; Howe JR
Surgery; 2014 Dec; 156(6):1359-65; discussion 1365-6. PubMed ID: 25456909
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets.
Faruki H; Mayhew GM; Fan C; Wilkerson MD; Parker S; Kam-Morgan L; Eisenberg M; Horten B; Hayes DN; Perou CM; Lai-Goldman M
Arch Pathol Lab Med; 2016 Jun; 140(6):536-42. PubMed ID: 26430809
[TBL] [Abstract][Full Text] [Related]
9. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.
Xu Q; Chen J; Ni S; Tan C; Xu M; Dong L; Yuan L; Wang Q; Du X
Mod Pathol; 2016 Jun; 29(6):546-56. PubMed ID: 26990976
[TBL] [Abstract][Full Text] [Related]
11. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation.
Mohanty SK; Kim SA; DeLair DF; Bose S; Laury AR; Chopra S; Mertens RB; Dhall D
Mod Pathol; 2016 Aug; 29(8):788-98. PubMed ID: 27125358
[TBL] [Abstract][Full Text] [Related]
12. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
Bellizzi AM
Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
15. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.
Handorf CR; Kulkarni A; Grenert JP; Weiss LM; Rogers WM; Kim OS; Monzon FA; Halks-Miller M; Anderson GG; Walker MG; Pillai R; Henner WD
Am J Surg Pathol; 2013 Jul; 37(7):1067-75. PubMed ID: 23648464
[TBL] [Abstract][Full Text] [Related]
16. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
[TBL] [Abstract][Full Text] [Related]
17. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
[TBL] [Abstract][Full Text] [Related]
18. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiles help identify the tissue of origin for metastatic brain cancers.
Wu AH; Drees JC; Wang H; VandenBerg SR; Lal A; Henner WD; Pillai R
Diagn Pathol; 2010 Apr; 5():26. PubMed ID: 20420692
[TBL] [Abstract][Full Text] [Related]
20. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy?
Koo J; Dhall D
Semin Diagn Pathol; 2015 Nov; 32(6):456-68. PubMed ID: 26573790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
